MF59
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
MF59 is an immunologic adjuvant developed using squalene. It is Novartis's proprietary adjuvant that is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory T cells. MF59 is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine. MF59 is used as an adjuvant in Canada, Europe and the United States. MF59 was developed in the 1990s by researchers at Chiron Corporation, a Novartis heritage company, acquired by Novartis in 2006.
MF59 is an immunologic adjuvant developed using squalene. It is Novartis's proprietary adjuvant that is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory T cells. MF59 is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine. MF59 is used as an adjuvant in Canada, Europe and the United States. MF59 was developed in the 1990s by researchers at Chiron Corporation, a Novartis heritage company, acquired by Novartis in 2006.
See also
AS03, another squalene based adjuvant
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372458437 under CC BY-SA 4.0; modifications have been made.